SCHEMBL23924823

SCHEMBL23924823

CCOC[C@@H](NC(=O)O)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
TAS1R3 Q7RTX0 2/20 0.35
TAS1R1 Q7RTX1 2/20 0.35
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
MMP8 P22894 1/20 0.33
REN P00797 3/20 0.32
CYP2D6 P10635 2/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP2C19 P33261 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924825 1.00 TSHR (0.36) TSHRTAS1R3TAS1R1MGAMGAA
SCHEMBL16165672 0.86 TSHR (0.35) TSHRMGAMGAASIMGAM2
SCHEMBL24369856 0.84 CA1 (0.37) TSHRCA1CA2CA7REN
SCHEMBL24369855 0.84 CA1 (0.37) TSHRCA1CA2CA7REN
SCHEMBL16176081 0.83 CA1 (0.35) TSHRTAS1R3TAS1R1CA1CA2
SCHEMBL25098434 0.82 CYP2C9 (0.39) TSHRTAS1R3TAS1R1CA1CA2
SCHEMBL24368981 0.82 TSHR (0.35) TSHRTAS1R3TAS1R1CA1CA2
SCHEMBL24368985 0.82 TSHR (0.35) TSHRTAS1R3TAS1R1CA1CA2
SCHEMBL9902847 0.79 MTNR1A (0.37) TSHRMGAMGAASIMGAM2
SCHEMBL18496308 0.79 MTNR1A (0.37) TSHRMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2026-02-03 US disclosed
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-09-12 US disclosed
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-07-02 US disclosed
EP-3887369-B1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-08 EP disclosed
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IRF3, IFNAR1, IFNG TSHR 1299/4885TAS1R3 1494/4885TAS1R1 1474/4885
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods IFNG, IFNAR1, IRF3 TSHR 3075/4885TAS1R3 2741/4885TAS1R1 2122/4885
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 TSHR 2977/4885TAS1R3 2366/4885TAS1R1 1550/4885
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, IRF3 TSHR 2977/4885TAS1R3 2366/4885TAS1R1 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.